HLS Therapeutics, Inc. (HLS.TO)
3.71
+0.01
(+0.27%)
CAD |
TSX |
Nov 13, 16:00
HLS Therapeutics Enterprise Value : 154.12M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 154.12M |
| November 12, 2026 | 153.82M |
| November 11, 2026 | 168.62M |
| November 10, 2026 | 167.41M |
| November 09, 2026 | 174.06M |
| November 06, 2026 | 175.27M |
| November 05, 2026 | 176.17M |
| November 04, 2026 | 170.43M |
| November 03, 2026 | 169.83M |
| November 02, 2026 | 177.08M |
| October 30, 2026 | 178.29M |
| October 29, 2026 | 179.80M |
| October 28, 2026 | 179.80M |
| October 27, 2026 | 180.10M |
| October 26, 2026 | 176.78M |
| October 23, 2026 | 172.85M |
| October 22, 2026 | 167.41M |
| October 21, 2026 | 166.81M |
| October 20, 2026 | 167.41M |
| October 19, 2026 | 165.60M |
| October 16, 2026 | 165.90M |
| October 15, 2026 | 167.11M |
| October 14, 2026 | 165.90M |
| October 13, 2026 | 164.39M |
| October 09, 2026 | 165.60M |
| Date | Value |
|---|---|
| October 08, 2026 | 168.92M |
| October 07, 2026 | 170.43M |
| October 06, 2026 | 168.92M |
| October 05, 2026 | 169.22M |
| October 02, 2026 | 158.95M |
| October 01, 2026 | 159.56M |
| September 30, 2026 | 168.92M |
| September 29, 2026 | 164.74M |
| September 28, 2026 | 165.05M |
| September 25, 2026 | 165.67M |
| September 24, 2026 | 163.17M |
| September 23, 2026 | 163.49M |
| September 22, 2026 | 163.80M |
| September 21, 2026 | 164.11M |
| September 18, 2026 | 162.24M |
| September 17, 2026 | 164.74M |
| September 16, 2026 | 165.99M |
| September 15, 2026 | 167.86M |
| September 14, 2026 | 169.74M |
| September 11, 2026 | 161.92M |
| September 10, 2026 | 156.61M |
| September 09, 2026 | 157.23M |
| September 08, 2026 | 158.17M |
| September 04, 2026 | 155.67M |
| September 03, 2026 | 152.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bausch Health Cos., Inc. | 31.74B |
| Cipher Pharmaceuticals, Inc. | 336.68M |
| BioSyent, Inc. | 195.94M |
| Revive Therapeutics Ltd. | 6.520M |
| Knight Therapeutics, Inc. | 1.082B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.116M |
| Revenue (Quarterly) | 19.82M |
| Total Expenses (Quarterly) | 22.93M |
| EPS Diluted (Quarterly) | -0.1009 |
| Gross Profit Margin (Quarterly) | 41.20% |
| Profit Margin (Quarterly) | -15.73% |
| Earnings Yield | -8.26% |
| Normalized Earnings Yield | -7.749 |